| 產品名稱 | SU-CCS-1 |
|---|---|
| 商品貨號 | B240979 |
| Organism | Homo sapiens, human |
| Tissue | soft tissue |
| Cell Type | clear cell sarcoma cell line |
| Product Format | frozen |
| Morphology | lymphoblast-like |
| Culture Properties | suspension |
| Biosafety Level | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease | clear cell sarcoma |
| Age | 16 |
| Gender | female |
| Ethnicity | Caucasian |
| Applications | A valuable tool to study EWS/ATF1 fusion gene produced by a consistent t(12;22)(q13;q12) chromosomal translocation. |
| Storage Conditions | liquid nitrogen vapor phase |
| Karyotype | t(12;22)(q13;q12) chromosomal translocation |
| Images |  |
| Derivation | SU-CCS-1 cell line was established from the pleural effusion of a 16-year-old Caucasian girl with clear cell sarcoma. She had been in excellent health until July 1975, when she developed a small, painful lump in her right heel. X-rays at that time were negative. The patient continued to have increased swelling and mild, intermittent right ankle pain until she was admitted to Children's Hospital at Stanford, CA, in May, 1976, with a 4-cm right inguinal mass and multiple pulmonary coin lesions. A biopsy of the right ankle mass revealed a cream-white tumor with the morphological features of clear cell sarcoma. Negative studies included a bone scan, a liver-spleen scan, a brain computer-assisted tomography scan, an i.v. pyelogram, a bone marrow aspirate and biopsy, and a lumbar puncture with spinal fluid evaluation. The patient was treated initially with pulse administration of vincristine, actinomycin D, and Cytoxan on May 17, 1976, without an objective response. In June 1976, she received one course of vincristine, Adriamycin, Cytoxan, and 5-(3,3-dimethyl-1 -triazenyl)-1 H-imidazole-4-carboxamide) chemotherapy followed by 4750 rads to the right groin for palliative treatment. She also was treated with high-dose methotrexate (300 mg/kg) with leucovorin rescue and high-dose Cytoxan (40 mg/kg/day) for 4 days again without response. In August 1976, she developed bilateral serosanguinous ma lignant pleural effusions which required Atabrine therapy. By mid-August, the patient had severe cachexia and developed congestive heart failure and pulmonary edema. Despite supportive care, she expired on September 12, 1976. Autopsy revealed extensive metastatic disease involving the lymphatics, bone marrow, lung, pleura, pericardium, liver, and a recurrent mass at the site of the primary tumor. |
| Clinical Data | 16 years
female
Caucasian |
| Oncogene | EWS/ATF1 fusion gene |
| Tumorigenic | Yes |
| Comments | Clear cell sarcoma (CCS) is associated with the EWS/ATF1 oncogene that is created by aberrant t(12;22)(q13;q12) chromosomal fusion of the Ewings Sarcoma oncogene (EWS) and the cellular transcription factor ATF1. SU-CCS-1 cell line has been revealed to express the EWS/ATF1 fusion protein, and been used as a valuable tool to study CCS biology and EWS/ATF1 fusion.
SU-CCS-1 cell line was also showed to actively produce a-melanotropin, S-100 antigen, and nerve growth factor, as well as produce bombesin, The malignant potential of the established SU-CCS-1 cell line has been confirmed by the original lab. The cells were injected into nude mice by s.c. and i.e. routes of inoculation. Both methods of inoculation were found to successfully produce tumors in the nude, athymic mouse. |
| Complete Growth Medium | The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing | Culture can be maintained by the adding of fresh medium or by centrifugation and re-suspension with fresh medium when the culture becomes high density. An inoculum of 2X 10(5) to 5 x 10(5) cells/mL is recommended. Subculture when cell concentration is between 1 x 10(6) and 2 x 10(6) cells/mL. A subcultivation ratio of 1:2 to 1:10 is recommended. Medium renewal every 2 to 3 days. |
| Cryopreservation | Freeze medium: Complete growth medium supplemented with an additional 20% fetal bovine serum and 10% DMSO.
Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions | Temperature: 37°C Atmosphere: air, 95%; carbon dioxide (CO2) 5% |
| Cells per Vial | 5.0x106 or more |
| STR Profile | Amelogenin: X
CSF1PO: 10, 11 D13S317: 8 D16S539: 11 D5S818: 12, 14 D7S820: 12 TH01: 6, 7 TPOX: 8, 11 vWA: 16, 17 |
| Name of Depositor | Alan L. Epstein |
| Year of Origin | 1977 |
| References | Epstein A, et al. Use of a Newly Established Human Cell Line (SU-CCS-1) to Demonstrate the Relationship of Clear Cell Sarcoma to Malignant Melanoma. Cancer Research 44(3):1265-1274, 1984. Pubmed: 6362860 Zucman J, et al. EWS and ATF-1 gene fusion induced by t(12:22) translocation in malignant melanoma of soft parts. Nature Genetics 4(4):341-345, 1993. Pubmed: 8401579 Li KK, et al. The melanocyte inducing factor MITF is stably expressed in cell lines form human clear cell sarcoma. Br. J. Cancer 89(6):1072-1078, 2003. PubMed: 12966428 Sonobe h, et al. Further characterization of the human clear cell sarcoma cell line HS-MM demonstrating a specific t(12;22)(q13;q12) translocation and hybrid EWS/ATF-1 transcript. J.Pathol. 187(5):594-597, 1999. PubMed: 10398127 |
| 梅經理 | 17280875617 | 1438578920 |
| 胡經理 | 13345964880 | 2438244627 |
| 周經理 | 17757487661 | 1296385441 |
| 于經理 | 18067160830 | 2088210172 |
| 沈經理 | 19548299266 | 2662369050 |
| 李經理 | 13626845108 | 972239479 |
